Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY-133 for S. aureus nasal decolonization
NCT06290557Phase 1Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Staphylococcus aureus colonization comparing Verum (HY-133) with Placebo (2 arms). Primary endpoint: ADRs/AEs/SAEs at Day 15. Started Jul 2024; status: recruiting.
02
Drugs
HY-133
03
Conditions
Staphylococcus aureus colonization
Beyond the preview
Go deeper on NCT06290557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290557.